Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

CDI Reports Third Quarter 2013 Financial Results

Published: Wednesday, November 13, 2013
Last Updated: Wednesday, November 13, 2013
Bookmark and Share
Revenues more than double.

Cellular Dynamics International, Inc. has reported financial results for the third quarter ended September 30, 2013.

“Trailing twelve months revenue as of September 30, 2013, more than doubled when compared to the corresponding period last year as did trailing twelve month average sales to our top 10 customers. Revenue for the third quarter also more than doubled when compared to the same period last year, and this growth was achieved with record gross margin from product sales of 79%," said Bob Palay, Chairman and CEO of CDI.

Palay continued, “A growing number of pharmaceutical companies are adopting CDI’s products for their research programs. By the end of the third quarter of 2013 CDI had sold to 142 customers for the trailing twelve months compared to 115 customers for the same period last year. Our top 10 customers averaged $704,000 in revenue for the trailing twelve months ended September 30, 2013, up from $313,000 for the same period last year. We believe these results add to the growing evidence that our iCell® and MyCell® products are becoming an industry standard for manufactured human cells.”

In addition, as recently announced, the Company received the Notice of Grant Award (NGA) from the California Institute of Regenerative Medicine (CIRM) to create a human induced pluripotent stem cell (iPSC) biobank from 3,000 individuals.

Receipt of the NGA signifies the entry into a definitive agreement with CIRM and the initiation of funding for the $16 million project. This contract resulted from the CIRM grant award to CDI announced last March.

The Company looks forward to the revenue from this contract contributing to our expected ongoing revenue growth in our base business.

Third Quarter 2013 Selected Financial Results
Revenue. Total revenues for the third quarter of 2013 were $2.5 million compared to $1.2 million for the third quarter of 2012, an increase of 108%. For the trailing twelve months ended September 30, 2013, total revenues were $10.7 million, compared to $4.6 million for the trailing twelve months ended September 30, 2012, an increase of 133%. Growth in total revenue is primarily attributable to growth in unit sales of the Company’s iCell products and significant increases in revenue from collaborations under our center of excellence agreements with Eli Lilly and Company and AstraZeneca UK Limited.

Costs and expenses. Total costs and expenses (excluding cost of product sales) were $9.3 million for the third quarter of 2013 compared to $6.4 million for the third quarter of 2012, an increase of 45%. This growth is attributable principally to an increase in supplies expense within our research and development organization, an increase in staffing within our sales and marketing organization and to general and administrative costs attributable to or triggered by our initial public offering. Approximately $669,000 of general and administrative expenses in the third quarter of 2013 reflect compensation and fee arrangements made effective as of the IPO date but attributable to service in the first and second quarter of 2013. Additionally, the Company incurred approximately $240,000 for travel and other expenses incurred in connection with our IPO. Tempering those operating cost increases, cost of product sales as a percentage of product sales revenue declined from 27% in the third quarter of 2012 to 21% in the third quarter of 2013, for a record gross margin from product sales of 79%. This compares favorably to the third quarter of 2012 gross margin from product sales of 73%.

Net loss. For the third quarter of 2013, net loss was $7.5 million, or $0.62 per share, compared with a net loss of $5.5 million, or $3.16 per share, for the third quarter of 2012. Weighted average shares outstanding for the third quarter of 2013 was 12.1 million versus 1.7 million for the third quarter of 2012. The difference in weighted average shares outstanding is principally attributable to both the common shares issued in our IPO and the conversion of our Series A and Series B preferred stock to common shares immediately prior to the consummation of our IPO.

Cash and cash equivalents. At September 30, 2013, cash and cash equivalents totaled $68.6 million.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cord Blood Registry and CDI Announce Collaboration
Collaboration to reprogram newborn stem cells into induced pluripotent stem cells.
Wednesday, January 14, 2015
Using iPSC-derived Cells to Coat Blood Vessels in Kidney Scaffolds
Cellular Dynamics and Northwestern University take first steps toward rebuilding an organ using manufactured human cells.
Tuesday, November 18, 2014
Cellular Dynamics International Reports Third Quarter 2014 Financial Results
Cellular Dynamics International, Inc. reported financial results for the third quarter and nine months ended September 30, 2014.
Tuesday, November 11, 2014
Cellular Dynamics Awarded $1.2 M NEI Contract
Contract will see company develop patient-derived stem cells in gear-up for age-related macular degeneration trial.
Tuesday, October 28, 2014
Cellular Dynamics Awarded NEI Contract
Contract awarded for the development of patient-derived stem cells in gear-up for age-related macular degeneration trial.
Monday, October 27, 2014
Cellular Dynamics Awarded U.S. Patent
Patent strengthens CDI’s position as leading manufacturer of human cells for research and clinical applications.
Friday, August 29, 2014
Cellular Dynamics Awarded Pluripotent Stem Cells Patents
Patents secure CDI’s position as leading manufacturer of human cells from most common, easily accessible donor source for research, drug discovery and regenerative medicine.
Thursday, July 10, 2014
Cellular Dynamics Q4 Revenues Increase 41%
Cellular Dynamics International, Inc. reported financial results for the fourth quarter and for the fiscal year ended December 31, 2013.
Tuesday, March 11, 2014
Cellular Dynamics Signs Agreement with Nestlé Institute of Health Sciences
Agreement will see company to supply iCell® and MyCell® products for nutritional research.
Wednesday, January 08, 2014
The Hamner Institutes and Cellular Dynamics Collaborate
The parties will develop predictive in vitro screening assays for chemical, environmental and pharmaceutical toxicology assessments.
Monday, December 09, 2013
Jain Foundation Signs Agreement with Cellular Dynamics
Company will create iPSC lines from patients with muscular dystrophies for use as disease models for basic research and drug discovery.
Wednesday, December 04, 2013
Cellular Dynamics Receives Formal Notice of Grant Award (NGA) for $16 Million Stem Cell Banking Project
NGA signifies entry into a definitive agreement and initiation of funding.
Tuesday, November 05, 2013
Cellular Dynamics Issued U.S. Patent
The patent relates to the method by which induced pluripotent stem cells are differentiated into the diverse types of endothelial and hematopoietic cells.
Thursday, October 17, 2013
Cellular Dynamics International Announces Closing of Initial Public Offering
Company announced the closing of its previously announced initial public offering of 3,846,000 shares of common stock at a price to the public of $12.00 per share.
Wednesday, July 31, 2013
Cellular Dynamics International Announces Launch of Initial Public Offering
Cellular Dynamics International, Inc. has commenced an initial public offering of 3,846,000 shares of common stock.
Thursday, July 11, 2013
Scientific News
Sorting Through Cellular Statistics
Aaron Dinner, professor in chemistry, and his graduate student Herman Gudjonson are trying to read the manual of life, DNA, as part of the Dinner group’s research into bioinformatics—the application of statistics to biological research.
Playing 'Tag' with Pollution lets Scientists See Who's It
Using a climate model that can tag sources of soot from different global regions and can track where it lands on the Tibetan Plateau, researchers have determined which areas around the plateau contribute the most soot — and where.
Women’s Immune System Genes Operate Differently from Men’s
A new technology reveals that immune system genes switch on and off differently in women and men, and the source of that variation is not primarily in the DNA.
Long Telomeres Associated with Increased Lung Cancer Risk
Genetic predisposition for long telomeres predicts increased lung adenocarcinoma risk.
First Artificial Ribosome Designed
Researchers at the University of Illinois at Chicago and Northwestern University have engineered a tethered ribosome that works nearly as well as the authentic cellular component, or organelle, that produces all the proteins and enzymes within the cell.
High-Resolution 3D Images Reveal the Muscle Mitochondrial Power Grid
NIH mouse study overturns scientific ideas on energy distribution in muscle.
Expanding the Brain
A team of researchers has identified more than 40 new “imprinted” genes, in which either the maternal or paternal copy of a gene is expressed while the other is silenced.
Identifying a Key Growth Factor in Cell Proliferation
Researchers discover that aspartate is a limiter of cell proliferation.
Study Uncovers Target for Preventing Huntington’s Disease
Scientists from Cardiff University believe that a treatment to prevent or delay the symptoms of Huntington’s disease could now be much closer, following a major breakthrough.
Paving the way to Better Ovarian Cancer Diagnosis
Aïcha BenTaieb will present her invention for automated identification of ovarian cancer’s many subtypes at an international conference this fall.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!